XML 64 R52.htm IDEA: XBRL DOCUMENT v3.25.2
Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Principal Changes in Scope of Consolidation (Details)
$ / shares in Units, € in Millions
 1 Months Ended 6 Months Ended
May 27, 2025
USD ($)
May 22, 2025
USD ($)
$ / shares
Apr. 30, 2025
EUR (€)
Jun. 30, 2025
EUR (€)
Dec. 31, 2024
EUR (€)
Jun. 30, 2024
EUR (€)
Jun. 02, 2025
USD ($)
$ / shares
Disclosure of detailed information about business combination [line items]              
Net cash flow on acquisition [1]       € 538.0   € 1,885.0 [2]  
Name of acquiree       ,      
Investments accounted for using the equity method       € 3,563.0 € 316.0    
Net Cash Inflow from Discontinued Operations [3]       10,742.0   0.0 [2]  
Other comprehensive income for the period       (4,774.0) € 1,199.0 1,233.0  
Net (income)/loss of the exchanged/held-for-exchange Animal Health business       2,881.0   € 202.0 [4]  
Opella              
Disclosure of detailed information about business combination [line items]              
Net Cash Inflow from Discontinued Operations       € 10,700.0      
Opella Business              
Disclosure of detailed information about business combination [line items]              
Net foreign exchange loss     € 500.0        
Investments accounted for using the equity method     3,200.0        
Net (income)/loss of the exchanged/held-for-exchange Animal Health business     2,700.0        
Assets (liabilities)     € 11,300.0        
Assets Acquisition              
Disclosure of detailed information about business combination [line items]              
Consideration transferred, acquisition-date fair value | $ $ 600,000,000            
Identifiable intangible assets recognised as of acquisition date | $ 562,000,000            
Net cash flow on acquisition | $ 602,000,000            
Potential Future Payments | $ $ 1,300,000,000            
Vigil Neuroscience, Inc              
Disclosure of detailed information about business combination [line items]              
Other comprehensive income for the period | $   $ 40,000,000          
Equity interests of acquirer | $   $ 470,000,000          
Equity Interests Of Acquirer, Per Share | $ / shares   $ 8.00          
Deferred Cash Payments | $   $ 2.00          
Percentage of voting equity interests acquired   12.00%          
Blueprint Medicines Corporation              
Disclosure of detailed information about business combination [line items]              
Consideration transferred, acquisition-date fair value | $             $ 9,100,000,000
Equity interests of acquirer | $             $ 9,500,000,000
Percentage of voting equity interests acquired             100.00%
Cash Transferred, Per Share | $ / shares             $ 129.00
[1] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For the six months ended June 30, 2025, this line item includes the net cash outflow arising from the acquisition of Dren-0201 (see Note B.1.2.). For the six months ended June 30, 2024 it includes the net cash outflow arising from the acquisition of Inhibrx, Inc.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] For the six months ended June 30, 2025, this amount includes €(667) million in respect of cash and cash equivalents held by Opella as of April 30, 2025.
[4] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.